Perspective Therapeutics, Inc. (CATX)

Current Report Filed: 2026-04-01

Key Insights

Perspective Therapeutics, Inc. has updated its corporate presentation, which could provide investors with new information about the company's latest developments and growth strategies.
The filing does not mention any material agreements, leadership changes, or earnings surprises, indicating a relatively routine update from the company.
Investors should review the updated corporate presentation for any insights into Perspective Therapeutics' pipeline, financial performance, or market opportunities.

Current Report Filed: 2026-03-16

Key Insights

Perspective Therapeutics, Inc. reported its financial results for the year ended December 31, 2025, providing investors with an update on the company's recent business activities.
The company posted an updated corporate presentation on its website, which investors can review to gain a better understanding of the company's strategic priorities and pipeline.
While the financial results and corporate presentation do not indicate any major or unexpected developments, the filing provides a regular update on the company's operations and ongoing initiatives.

Annual Report Filed: 2026-03-16

Key Insights

The company has incurred significant research and development expenses, suggesting it is investing heavily in new product development.
The company has raised capital through various public offerings and warrant issuances, indicating it may be funding its operations and growth initiatives.
The company has discontinued its Cesium-131 business, potentially shifting its strategic focus to other areas.

Insider Trading Filed: 2026-03-04

Key Insights

Markus Puhlmann, the Chief Medical Officer of Perspective Therapeutics, Inc. (CATX), was granted a stock option to acquire 150,000 shares of the company's common stock, indicating management's confidence in the company's future prospects.
The option has a 10-year term and vests over 4 years in equal monthly installments, aligning Puhlmann's interests with those of long-term shareholders.
The exercise price of $5.35 per share represents a premium to the current market price, suggesting the board believes the stock is undervalued and has potential for future growth.

Insider Trading Filed: 2026-03-04

Key Insights

Jonathan Hunt, the Chief Accounting Officer, has been granted a stock option of 90,000 shares of the company's common stock, vesting over 4 years. This indicates the company's commitment to incentivize and retain key management.
The stock option has an exercise price of $5.35, which is the current market price, suggesting the grant is intended to align management's interests with shareholders.
The timing of the grant, in early March 2026, may signal the company's confidence in its near-term outlook and a desire to reward and motivate its accounting leadership.

Insider Trading Filed: 2026-03-04

Key Insights

The reporting person, Johan M. Spoor, who is the Chief Executive Officer and a Director of Perspective Therapeutics, Inc., has been granted a stock option for 735,000 shares of the company's common stock. This indicates the company is incentivizing its top executive with a significant equity award, potentially aligning his interests with shareholders.
The stock option has a 10-year term and vests over four years, suggesting a long-term focus on the company's growth and performance.
The exercise price of the option is $5.35, which could provide the reporting person with an opportunity to profit if the company's stock price increases over time.

Insider Trading Filed: 2026-03-04

Key Insights

Lori A. Woods, a director of Perspective Therapeutics, Inc., has been granted 50,000 stock options with an exercise price of $5.35 and a 10-year expiration date.
The stock option grant was approved by the company's Board of Directors on January 26, 2026, and the grant date is March 2, 2026, suggesting this is part of the director's annual equity compensation.
The stock options vest in full on March 2, 2027, subject to the director's continued service on the vesting date, indicating this is a standard time-based vesting schedule.

Insider Trading Filed: 2026-03-04

Key Insights

Heidi Henson, a director of Perspective Therapeutics, Inc. (CATX), has been granted 50,000 stock options with a strike price of $5.35 and a vesting date of March 2, 2027, as part of her annual equity award.
The option grant was approved by the company's Board of Directors on January 26, 2026, indicating the company is providing long-term incentives to its directors.
The insider transaction represents a direct ownership of 50,000 shares, which could signal Henson's confidence in the company's future prospects.

Insider Trading Filed: 2026-03-04

Key Insights

Robert F. Williamson, III, a director of Perspective Therapeutics, Inc. (CATX), has been granted a stock option to purchase 50,000 shares of the company's common stock at $5.35 per share.
The option grant was approved by the company's Board of Directors on January 26, 2026, with a vesting date of March 2, 2027, subject to Williamson's continued service on the vesting date.
Insider transactions, such as this option grant, can provide insights into management's confidence in the company's future performance and align their interests with shareholders.

Insider Trading Filed: 2026-03-04

Key Insights

The filing indicates that Frank Morich, a director of Perspective Therapeutics, Inc. (CATX), has been granted a stock option to acquire 50,000 shares of the company's common stock.
The stock option has an exercise price of $5.35 per share and a 10-year term, vesting fully on March 2, 2027, subject to Morich's continued service on the board.
This stock option award appears to be Morich's annual equity compensation for 2026, as approved by the company's board of directors on January 26, 2026.

Insider Trading Filed: 2026-03-04

Key Insights

The reporting person, Maria E. Martinez, has been granted a stock option to acquire 50,000 shares of the issuer's common stock, vesting in full on March 2, 2027.
This appears to be an annual equity award for Ms. Martinez's role as a director of the issuer, Perspective Therapeutics, Inc.
The option has an exercise price of $5.35 per share, which may provide an opportunity for Ms. Martinez to benefit from potential share price appreciation in the future.

Current Report Filed: 2026-02-03

Key Insights

Perspective Therapeutics, Inc. (CATX) successfully raised approximately $175 million through a public offering, which they plan to use to advance their clinical development pipeline and invest in manufacturing capabilities.
The company issued pre-funded warrants in addition to common stock, providing potential upside for investors if the warrants are exercised in the future.
The proceeds from the offering are expected to strengthen the company's financial position and support its strategic initiatives, though the specifics of how the funds will be used are not yet detailed.

Current Report Filed: 2026-02-02

Key Insights

Perspective Therapeutics, Inc. provided a corporate presentation with preliminary financial data for the year ended December 31, 2025, which has not been audited or reviewed by the company's independent accounting firm.
The company's actual results as of December 31, 2025 may differ from the preliminary financial data due to ongoing closing procedures and final adjustments.
Investors should wait for the company to report its audited financial results before drawing conclusions about the company's financial performance.

Current Report Filed: 2026-01-14

Key Insights

Perspective Therapeutics, Inc. has updated its corporate presentation, which may provide investors with new information on the company's strategic direction and product pipeline.
The filing does not indicate any material events or agreements, suggesting a routine regulatory filing without significant news.
As an NYSE American-listed company, Perspective Therapeutics is likely an emerging growth biopharmaceutical firm, which may carry higher risks and volatility for investors.

Current Report Filed: 2026-01-12

Key Insights

Perspective Therapeutics, Inc. has issued a press release on January 12, 2026 to provide business updates and strategic priorities.
The company's trading symbol on the NYSE American exchange is CATX, indicating it is a publicly traded entity.
The filing does not provide any financial or operational details, so the significance of the update is unclear from the information provided.

Current Report Filed: 2026-01-09

Key Insights

Perspective Therapeutics announced updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with neuroendocrine tumors, which will be presented at the 2026 ASCO GI Cancers Symposium.
The company's lead product candidate, [212Pb]VMT-α-NET, is being developed for the treatment of unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors.
The updated interim data release suggests the company is making progress in its clinical development program, which could potentially benefit investors if the data is positive.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information